Cogent Biosciences (COGT) Cash & Current Investments: 2017-2021
Historic Cash & Current Investments for Cogent Biosciences (COGT) over the last 4 years, with Sep 2021 value amounting to $202.9 million.
- Cogent Biosciences' Cash & Current Investments rose 56.77% to $202.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $893.9 million, marking a year-over-year increase of 310.45%. This contributed to the annual value of $242.2 million for FY2020, which is 547.15% up from last year.
- Cogent Biosciences' Cash & Current Investments amounted to $202.9 million in Q3 2021, which was down 6.98% from $218.1 million recorded in Q2 2021.
- In the past 5 years, Cogent Biosciences' Cash & Current Investments ranged from a high of $242.2 million in Q4 2020 and a low of $21.3 million during Q2 2020.
- For the 3-year period, Cogent Biosciences' Cash & Current Investments averaged around $116.4 million, with its median value being $67.1 million (2019).
- In the last 5 years, Cogent Biosciences' Cash & Current Investments tumbled by 61.88% in 2019 and then skyrocketed by 921.95% in 2021.
- Over the past 5 years, Cogent Biosciences' Cash & Current Investments (Quarterly) stood at $49.6 million in 2017, then skyrocketed by 97.56% to $97.9 million in 2018, then crashed by 61.79% to $37.4 million in 2019, then soared by 547.15% to $242.2 million in 2020, then skyrocketed by 56.77% to $202.9 million in 2021.
- Its last three reported values are $202.9 million in Q3 2021, $218.1 million for Q2 2021, and $230.7 million during Q1 2021.